|Slideshows|April 28, 2021

Top Treatment Modalities for Depression

The psychiatrist's armamentarium to treat depression holds promise with a growing arsenal of integrative and pharmacologic options.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Managing Treatment-Resistant Depression: Insights From David Medina, MD, FAPA

ByDavid Medina, MD, FAPA

December 2nd 2025

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State

ByGrace Thetford-Harvey, MD,Tessa Manning, MD

December 2nd 2025

Bromine and Bromism: What’s Old Is New Again

BySharon Packer, MD

December 1st 2025

Looking Back: Key Insights from November 2025

ByJessica Walters

November 28th 2025

lithium suicide bipolar major depressive disorder

Lithium Reduces Risk of Suicide and Recurrent Episodes of Bipolar and Major Depressive Disorders

ByKenneth J. Bender, PharmD, MA

November 26th 2025

Latest CME

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Top Treatment Modalities for Depression

Newsletter

Related Content

Managing Treatment-Resistant Depression: Insights From David Medina, MD, FAPA

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State

Bromine and Bromism: What’s Old Is New Again

Looking Back: Key Insights from November 2025

Lithium Reduces Risk of Suicide and Recurrent Episodes of Bipolar and Major Depressive Disorders

Latest CME

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State

Antidepressants Assessed for Reducing Negative Symptoms of Schizophrenia

A Not So Happy Third Birthday for ChatGPT

November in Review: Updates on the Psychiatric Treatment Pipeline

Managing Treatment-Resistant Depression: Insights From David Medina, MD, FAPA